Human interleukin-2

Generic Name: Human interleukin-2

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: FNO32LO217

Background: Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

TILT Biotherapeutics Presents Clinical Data on TILT-123

TILT Biotherapeutics presents Phase I data on TILT-123, an intravenous oncolytic adenovirus therapy for advanced solid cancers, at ESMO 2024, demonstrating safety and tumor transduction.

Related Clinical Trials:

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer.

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

pharmabiz.com

4 months ago

Innovent receives US FDA fast track designation for IBI363 as monotherapy for advanced melanoma

Innovent Biologics' PD-1/IL-2a-bias Bispecific Antibody Fusion Protein (IBI363) received Fast Track Designation from the FDA for treating melanoma. Phase 1/2 trials in China, the US, and Australia show promising efficacy, with 29.7% ORR and 73.0% DCR in melanoma patients previously treated with immunotherapy. IBI363 aims to address unmet needs for immunotherapy-resistant melanoma.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy